Clopidogrel
Product Images NDC 68071-2813

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 68071-2813). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2813 9)

This is a description of NuCare Pharmaceuticals' product with the name DRoaM. DRoaM is a 75mg film-coated tablet containing Clopidogrel Bisulfate USP. Each tablet has 97.875mg of Clopidogrel Bisulfate USP, equivalent to 75mg of Clopidogrel base. The tablets come in bottles of 90 tablets, with a unique serial number and an expiration date of 00-00. The manufacturer's label contains a list of all ingredients. Customers are advised to store the product within temperatures of 68-77°F and should keep it out of the reach of children. Customers who need more information are directed to contact the manufacturer or call 1-800-FDA-1088.*

FDA Label Image

Figure (Clopidogrel Fig1)

This is a graph displaying the cumulative event rate for fatal or non-fatal vascular events for both Aspirin and Clopidogrel Bisulfate over a period of 36 months of follow-up. The graph shows that there is a statistically significant difference between the two treatments (p=0.045).*

FDA Label Image

Figure (Clopidogrel Fig2)

This is a table displaying the cumulative event rate for cardiovascular death, myocardial infarction, and stroke over a period of follow-up months. The data compares the use of placebo (with aspirin) and clopidogrel bisulfate (with aspirin) and shows a statistically significant difference in the event rate between the two treatments. No other information or context is available.*

FDA Label Image

Figure (Clopidogrel Fig3)

FDA Label Image

Figure (Clopidogrel Fig4)

This text is a report of clinical trial results comparing the effects of a placebo versus a medication called Clopidogrel. The report includes the percentage of deaths before the first discharge in both groups, as well as the number of deaths and proportional risk reduction in the Clopidogrel group. It also indicates the days since randomization when the measurements were taken (up to 28 days).*

FDA Label Image

Figure (Clopidogrel Fig5)

This text appears to be a brief summary of the results of a clinical trial testing the effectiveness of Clopidogrel in reducing the risk of death, re-infarction, or stroke in patients before their first discharge. The trial included a group treated with a placebo and a group treated with Clopidogrel, with the latter group experiencing a 9% reduction in risk of these events (compared to the placebo group). There is also a reference to randomization.*

FDA Label Image

Figure (Clopidogrel Fig6)

FDA Label Image

Change Relative To Clopidogrel Bisulfate Administered Alone (Clopidogrel Fig8)

FDA Label Image

Figure (Clopidogrel Fig9)

This appears to be a table or chart of some kind with information related to stroke, PAD (peripheral artery disease), and two drugs: Clopidogrel and Aspirin. The table includes four years of data (06-09) and another set of years (0, 11-13) with unclear context. The final column includes a hazard ratio with a 95% confidence interval. It is difficult to provide more context or a specific use for this data without additional information.*

FDA Label Image

Clopidogrel-str (Clopidogrel Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.